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Table 1. Comparison of graft characteristics derived from Table 2
and Figure 4 of Ram et al study [1]
Control Flow Stenosis
group group group
N = 34 N = 32 N = 35
1 No. of rethrombosis eventsa 2 14 1
2 Entry PTA rate/patient yearb 1.46 0.58 0.70
estimation from Table 2
3 Entry graft age days S/M 1.6 1.5 1.2
4 Entry no. of PTA S/M 1.6 1.4 1.5
S/M, ratio of standard deviation to mean value.
aNot included are rethrombosis events that occurred before Qa could be
measured.
bEntry thrombosis rates, rates of preemptive PTA (the crucial parameters of
this study), and methodology of calculations were not presented by authors in
Table 2 nor in Methods. The author (W.D.P.) declined to clarify. We estimated
PTA rate/patient by dividing entry PTA events by entry graft age days.
on the value of variation coefficient. This study would
need at least 140 patients in each group to credibly iden-
tify differences of 30% (95th percent CI) [4]. At 32 to 35
patients per group, observed variations between groups
must differ by a factor of more then 2.5 to have statistical
credibility.
The fact that data of just one to three grafts re-
verses major statistical outcomes of a 2.3-year study gives
evidence to inadequate group size in relation to the
study purpose. This compromises the authors’ clinical
conclusions.
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Reply from the Authors
Krivitski et al [1] represent Transonic Corporation, the
manufacturer of the ultrasound dilution device that is
widely used to measure access blood flow (Qa). We share
their disappointment that Qa surveillance did not prolong
graft life in our randomized controlled trial [2]. We have
the following response to their criticisms:
1. They have not accurately described the context of
our comments concerning previous studies. Our in-
tent was to show that the role of surveillance has
not yet been established.
2. They claim that our study had inadequate sample
size and that there was poor comparability between
groups.
A. The primary end point of our study was graft sur-
vival. Our 95% CI shows that if Qa surveillance
increased probability of graft survival, it was by
less than 0.25 at 2 years. This result shows that
if surveillance improves survival, it is modest
at best, and far less than in landmark, nonran-
domized studies (which have reported 4-fold im-
provements in survival). Krivitski et al are apply-
ing an unrealistic standard when they demand
adequate sample size for all possible compar-
isons, whether or not they are study end points.
B. Our study used the proportional hazards model
to test whether adjustment for the influence of
a number of variables (graft age, etc.) affected
study outcome. We reached the same conclusion:
there is no evidence that surveillance prolonged
graft life.
3. Their calculation of rethrombosis events is invalid
since they did not include all such events. Moreover,
note that the relatively high thrombosis rate in the
flow group was due to failures of flow surveillance.
4. Their comparison of prestudy PTA rates is invalid
since it did not take into account when PTAs oc-
curred (PTAs just before vs. remote from study en-
try do not have the same significance).
We appreciate the passionate commitment of mem-
bers of Transonic Corporation to their ultrasound dilu-
tion device. Nevertheless, we hope this commitment will
not keep them from applying a balanced view when eval-
uating surveillance studies. We believe they have much to
contribute to improving the management of hemodialysis
accesses.
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